ClinicalTrials.gg
RecruitingNCT07465965Updated Mar 12, 2026

A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults

A Phase 1 interventional study of Semaglutide Nasal Spray and Placebo in Overweight and Obesity, sponsored by Shanghai World Leader Pharmaceutical Co., Ltd.. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-12.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Shanghai World Leader Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 143 studies testing semaglutide in Obesity — 68 open to participants now, 77 under way, 14 of them phase 3. Semaglutide · Obesity.

Planned enrollment
99th of 143
60 · median 100
Started
2026
with 29 others
Phase 1
19 of 143
9 open now
Primary completion
2026-08
later than 12 of 76 live
Registered
114th of 143
by date

Among the 143 studies testing semaglutide in Obesity, this one is the 99th largest by planned enrollment, is one of 30 that started in 2026, is one of 19 in phase 1, reaches primary completion later than 12 of the 76 other live ones, and was the 114th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

68 of the 143 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

62 more — sign in →

By country, each count listing its studies:

All 68 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 143 studies testing semaglutide in Obesity, or all of them as a file.
02

Study summary

The specific aim of this study is to examine the Safety, Tolerability and Pharmacokinetic of Semaglutide Nasal Spray compared with placebo and positive control in Adult Overweight or Obese Participants.

03

Conditions studied

  • Overweight
  • Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's planned enrollment of 60 is below the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

This is the only study on the registry with Shanghai World Leader Pharmaceutical Co., Ltd. as lead sponsor.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants aged ≥18 years and ≤ 65 years.
  2. (BMI) at screening between 27.0 and 35.0 kg/m² (inclusive).
  3. Weight change of no more than ±5% during the 3 months prior to screening with diet and exercise alone (self-reported).
  4. Participants (including males) must have no plans for conception during the study and within 3 months after the last administration, and must agree to use effective methods and refrain from donating sperm or eggs during this period.
  5. Negative anti- antibody test result at screening.
  6. Participants must fully understand the trial objectives, nature, procedures, and potential adverse reactions, voluntarily participate, be able to communicate well with the investigators, comply with all study requirements, and sign the form before any study procedures begin.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of type 1, type 2, or other forms of diabetes mellitus.
  2. Prior diagnosis of obesity caused by monogenic mutations or other medical conditions, including but not limited to hypothalamic obesity, pituitary obesity, hypothyroidism-related obesity, Cushing's syndrome, insulinoma, acromegaly, or hypogonadism.
  3. Prior history of bariatric surgery (excluding participants who had liposuction, abdominoplasty, intragastric balloon removal, or duodenal-jejunal bypass sleeve removal >1 year prior), or plan to undergo bariatric surgery or use weight-loss devices during the study.
  4. Use of any of the following treatments within 3 months prior to screening:

    1. Approved or unapproved anti-obesity medications (e.g., liraglutide, semaglutide, benaglutide, tirzepatide, orlistat, phentermine/topiramate, naltrexone/bupropion), or herbal supplements, health products, meal replacements, or weight-loss capsules that may affect body weight;
    2. Any glucagon-like peptide-1 (GLP-1) receptor agonists, GLP-1 related multi-agonists (e.g., GLP-1/glucose-dependent insulinotropic polypeptide [GIP] dual agonists, GLP-1/glucagon [GCG] dual agonists, GLP-1/GIP/GCG triple agonists), or combination preparations containing GLP-1 receptor agonists;
    3. Any antidiabetic medications (e.g., odium-glucose cotransporter-2 inhibitors (SGLT2) inhibitors, metformin, alpha-glucosidase inhibitors, insulin);
    4. Any other treatments known to affect body weight (e.g., cause weight loss or weight gain), including:

      • Systemic therapy (intravenous or oral) for >1 week
      • Tricyclic antidepressants (e.g., imipramine, amitriptyline, doxepin)
      • Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, paroxetine, sertraline, fluvoxamine)
      • Antipsychotics/antiepileptics (e.g., imipramine, amitriptyline, mirtazapine, phenelzine, chlorpromazine HCl, clozapine, olanzapine, valproate derivatives, lithium preparations, thioridazine)
      • Antihistamines (e.g., cyproheptadine, ketotifen, astemizole).
    5. Any drugs, vaccines, or medical devices.
  5. Laboratory abnormalities at screening meeting any of the following:

    1. (HbA1c) ≥6.5% or fasting glucose ≥7.0 mmol/L;
    2. Uncontrolled hypertension, systolic blood pressure (SBP) ≥160 mmHg and/or diastolic blood pressure (DBP) ≥100 mmHg;
    3. Thyroid-stimulating hormone (TSH) >4.2 or \<0.27 mIU/L;
    4. (ALT) or aspartate aminotransferase (AST) ≥1.5 × (ULN), or total ≥1.5 × ULN;
    5. Fasting triglycerides >3.42 mmol/L;
    6. Serum amylase or lipase ≥1.5×ULN;
    7. Calcitonin > ULN;
    8. Estimated (eGFR) ≤80 mL/min/1.73 m²;
    9. findings: HR \<40 or >100 bpm, second- or third- degree atrioventricular (AV) block, long syndrome, QTcF >450 ms (male) or >470 ms (female), left bundle branch block (LBBB), complete right bundle branch block (RBBB), Wolff-Parkinson-White (WPW) syndrome, or other clinically significant arrhythmias (e.g., paroxysmal supraventricular tachycardia (SVT), atrial flutter/fibrillation, ventricular flutter or fibrillation, sick sinus syndrome) deemed unsuitable by the investigator.
  6. History of acute or chronic pancreatitis, or symptomatic gallbladder disease (except cholecystectomy).
  7. Participants with clinically significant abnormalities during nasal examination (including external nose and nasal cavity inspection) as determined by the investigator at screening.
  8. Nasal or sinus surgery or nasal trauma within 3 months prior to screening, not fully healed.
  9. Presence of nasal mucosal erosion, septal ulceration/perforation, or other nasal conditions (e.g., acute or chronic sinusitis, drug-induced rhinitis, allergic rhinitis, nasal polyps) that may affect intranasal drug deposition, as determined by the investigator.
  10. Participants with extensive scars or large tattoos on the abdomen, thighs, or upper arms that may interfere with drug administration.
  11. History of thyroid disease or abnormal thyroid function requiring treatment, deemed clinically significant.
  12. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).
  13. Any diagnosed within 5 years (except cured basal cell carcinoma, cervical carcinoma in situ, localized prostate cancer post-surgery, or ductal carcinoma in situ post-surgery).
  14. History of major cardiovascular or cerebrovascular events: a) MI, PCI/CABG, valvular surgery, clinically significant arrhythmias requiring treatment, unstable angina, , stroke within 6 months prior to screening, b) Class III-IV heart failure.
  15. Clinically significant gastrointestinal (GI) diseases at screening or within the screening period: pyloric obstruction, ileus, delayed gastric emptying, inflammatory bowel disease (IBD), gastroparesis, gastroesophageal reflux disease (GERD), active peptic ulcer.
  16. Participants positive for surface antigen anti- virus antibody, or RPR at screening;
  17. Participants with upper respiratory tract infection occurring within 7 days before administration.
  18. Major depressive disorder or other severe psychiatric illness (e.g., schizophrenia, schizoaffective disorder, paranoid psychosis, bipolar disorder, epilepsy-related psychosis, intellectual disability with psychiatric symptoms) within 2 years before screening, or any history of self-harm or suicidal behavior, or participants with any suicidal ideation of type 4 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan) or type 5 (Active Suicidal Ideation with Specific Plan and Intent) on the C-SSRS.
  19. Blood donation within 3 months or total blood loss ≥400 mL within 6 months (excluding menstruation) prior to screening; planned donation within 3 months post-study.
  20. History of vasovagal syncope or intolerance to venipuncture/IV cannulation.
  21. Participants with a history of or known/suspected allergy to GLP-1 receptor agonists or any in the study drug formulation.
  22. History of alcohol abuse within 1 year prior to screening through check-in, defined as an average consumption >14 units/week (1 unit = 360 mL beer, 45 mL 40% spirits, or 150 mL wine); unwilling to abstain from alcohol use during study, or a positive breath alcohol test (>0.0 mg/100 mL).
  23. Smoking >5 cigarettes/day within 3 months prior to screening, or unwilling to abstain during study.
  24. History of substance abuse (including non-medical use of narcotics or psychotropic substances) within 1 year prior to screening through check-in; Positive drug screening test for: morphine, methamphetamine ("ice"), 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"), tetrahydrocannabinol (THC, cannabis), etc.
  25. Female Participants who are pregnant or breastfeeding, or with positive serum pregnancy test results at screening, or positive urine pregnancy test at check-in (Day -1);
  26. Any other condition deemed by the investigator to render the participant unsuitable for participation.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Cohort A0 : Semaglutide Nasal Spray

    Drug: Semaglutide Nasal Spray

  • Experimental
    Cohort A1: Semaglutide nasal spray and placebo

    Drug: Semaglutide Nasal Spray · Drug: Placebo

  • Experimental
    Cohort A2:Semaglutide nasal spray and placebo

    Drug: Semaglutide Nasal Spray · Drug: Placebo

  • Active comparator
    Cohort A3: Semaglutide injection

    Drug: Semaglutide Injection

Interventions

07

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax)

    Time frame: Day 1 to Day 36 after administration

  2. Time to maximum concentration(Tmax)

    Time frame: Day 1 to Day 36 after administration

  3. Area under the concentration-time curve from time 0 to time t (AUC0-t)

    Time frame: Day 1 to Day 36 after administration

  4. Area under the concentration-time curve from time 0 to infinity(AUC0-∞)

    Time frame: Day 1 to Day 36 after administration

  5. Percentage of AUC extrapolated(AUC%Extrap)

    Time frame: Day 1 to Day 36 after administration

  6. Elimination half-life / Terminal half-life(t1/2)

    Time frame: Day 1 to Day 36 after administration

  7. Apparent volume of distribution during terminal phase, adjusted for bioavailability (Vz/F)

    Time frame: Day 1 to Day 36 after administration

  8. Apparent clearance, adjusted for bioavailability(CL/F)

    Time frame: Day 1 to Day 36 after administration

  9. Terminal elimination rate constant(λz)

    Time frame: Day 1 to Day 36 after administration

  10. Absolute bioavailability(F)

    Time frame: Day 1 to Day 36 after administration

  11. Incidence and severity of treatment emergent adverse events (TEAEs)

    Time frame: Day 1 to Day 36 after administration

  12. 12-Lead-ECGs(Electrocardiograms )

    Time frame: Day 1 to Day 36 after administration

  13. Temperature

    Time frame: Day 1 to Day 36 after administration

  14. Pulse

    Time frame: Day 1 to Day 36 after administration

  15. Respiratory rate

    Time frame: Day 1 to Day 36 after administration

  16. Blood pressure

    Time frame: Day 1 to Day 36 after administration

  17. Urinalysis

    Time frame: Day 1 to Day 36 after administration

  18. Blood biochemistry

    Alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin, γ-glutamyl transferase, alkaline phosphatase, total protein, albumin, urea, uric acid, creatinine, calcium, chloride, potassium, sodium, phosphorus, total cholesterol, triglycerides, fasting blood glucose, creatine kinase, lactate dehydrogenase, amylase, lipase.

    Time frame: Day 1 to Day 36 after administration

  19. Thyroid function

    Thyroid-stimulating hormone, total tri-iodothyronine, total thyroxine, free tri-iodothyronine, free thyroxine

    Time frame: Day 1 to Day 36 after administration

  20. Virology test

    Time frame: Day 1 to Day 36 after administration

  21. Urine pregnancy test

    Time frame: Day 1 to Day 36 after administration

  22. Physical examination, includes: head, ears, eyes, nose and throat, skin, lymph nodes, neck, chest, abdomen, heart, cardiovascular, musculoskeletal system/extremities, neurological system and body weight.

    Time frame: Day 1 to Day 4 after administration

  23. Hemoglobin

    Time frame: Day 1 to Day 36 after administration

  24. Hematocrit

    Time frame: Day 1 to Day 36 after administration

  25. Red blood cell count

    Time frame: Day 1 to day 36

  26. White blood cell count

    Time frame: Day 1 to day36

  27. Platelet count

    Time frame: Day 1 to day 36

  28. Neutrophil percentage

    Time frame: day 1 to day 36

  29. Eosinophil percentage

    Time frame: day 1 to day 36

  30. Basophil percentage

    Time frame: day 1 to day 36

  31. Monocyte percentage

    Time frame: day 1 to day 36

  32. Lymphocyte percentage

    Time frame: day 1 to day 36

  33. Activated partial thromboplastin time

    Time frame: Day 1 to day 36

  34. Prothrombin time

    Time frame: day 1 to day 36

  35. Fibrinogen

    Time frame: day 1 to day 36

  36. Thrombin time

    Time frame: day 1 to day 36

Secondary outcomes

  1. Positive rate of Anti-Drug Antibody (ADA)

    Time frame: Day 1 to Day 29 after administration

  2. Titer of Anti-Drug Antibody (ADA)

    Time frame: Day 1 to Day 29 after administration

  3. Positive rate of Neutralizing antibody (Nab)

    if ADA is positive

    Time frame: Day 1 to Day 29 after administration

  4. Titer of Neutralizing antibody (Nab)

    if ADA is positive

    Time frame: Day 1 to Day 29 after administration

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Aug 2026, 5 months after the start.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 5 months is below that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2026
First posted
Mar 12, 2026
StartActual
Mar 2, 2026
Primary completionEst.
Aug 21, 2026
CompletionEst.
Aug 30, 2026
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07465965
Lead sponsor
Shanghai World Leader Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Mar 12, 2026
Start date
Mar 2, 2026
Primary completion
Aug 21, 2026 (estimated)
Completion
Aug 30, 2026 (estimated)
Last update
Mar 12, 2026

Study contacts

Guiyi Huang, Master
Contact
huangguiyi@worldleadertdds.com
0086-18640027113

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion